Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernando Quevedo

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
The Prostate|March 16, 2023
Dynamic assessment of serum chromogranin A and treatment response with abiraterone acetate in metastatic castration-resistant prostate cancerAkeem R Lewis, Brian A Costello, Fernando Quevedo, et al.
The Journal of Urology|June 20, 2023
The Impact of Metastasis Histopathology on Oncologic Outcomes for Patients With Surgically Resected Metastatic Renal Cell CarcinomaRodrigo Rodrigues Pessoa, Reza Nabavizadeh, Fernando Quevedo, et al.
The Journal of Urology|September 17, 2017
Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using <sup>11</sup>C-Choline Positron Emission Tomography and Multiparametric Pelvic Magnetic Resonance ImagingAvinash Nehra, William P Parker, Rimki Haloi, et al.
Investigational New Drugs|July 27, 2013
Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignanciesShaji K Kumar, James Jett, Randolph Marks, et al.
The Prostate|June 2, 2022
The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastasesAlex J Liu, Heidi E Kosiorek, Benjamin E Ueberroth, et al.
European Urology|August 18, 2014
Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancerXiaoyi Huang, Tiezheng Yuan, Meihua Liang, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 21, 2025
[<sup>177</sup>Lu] Lu-PSMA-617 treatment for metastatic castration-resistant prostate cancer (mCRPC) with cerebral and cerebellar metastasesGokce Belge Bilgin, Cem Bilgin, Brian J Burkett, et al.
Advances in Radiation Oncology|November 2, 2019
<sup>11</sup>C-Choline PET Guided Salvage Radiation Therapy for Isolated Pelvic and Paraortic Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Rationale and Early Genitourinary or Gastrointestinal ToxicitiesKrishan R Jethwa, Christopher D Hellekson, Jaden D Evans, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 31, 2025
Defining NECTIN4 Amplification and Protein Expression in Urothelial Carcinoma and Histologic SubtypesJohn C Cheville, Jacob J Orme, Sounak Gupta, et al.
Journal of Pain and Symptom Management|May 5, 2025
Olanzapine for Managing Side Effects From Antiangiogenic Tyrosine-Kinase InhibitorsRegina M Koch, Miguel Muniz, Candy S Peskey, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
The Prostate|March 16, 2023
Dynamic assessment of serum chromogranin A and treatment response with abiraterone acetate in metastatic castration-resistant prostate cancerAkeem R Lewis, Brian A Costello, Fernando Quevedo, et al.
The Journal of Urology|June 20, 2023
The Impact of Metastasis Histopathology on Oncologic Outcomes for Patients With Surgically Resected Metastatic Renal Cell CarcinomaRodrigo Rodrigues Pessoa, Reza Nabavizadeh, Fernando Quevedo, et al.
The Journal of Urology|September 17, 2017
Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using <sup>11</sup>C-Choline Positron Emission Tomography and Multiparametric Pelvic Magnetic Resonance ImagingAvinash Nehra, William P Parker, Rimki Haloi, et al.
Investigational New Drugs|July 27, 2013
Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignanciesShaji K Kumar, James Jett, Randolph Marks, et al.
The Prostate|June 2, 2022
The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastasesAlex J Liu, Heidi E Kosiorek, Benjamin E Ueberroth, et al.
European Urology|August 18, 2014
Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancerXiaoyi Huang, Tiezheng Yuan, Meihua Liang, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 21, 2025
[<sup>177</sup>Lu] Lu-PSMA-617 treatment for metastatic castration-resistant prostate cancer (mCRPC) with cerebral and cerebellar metastasesGokce Belge Bilgin, Cem Bilgin, Brian J Burkett, et al.
Advances in Radiation Oncology|November 2, 2019
<sup>11</sup>C-Choline PET Guided Salvage Radiation Therapy for Isolated Pelvic and Paraortic Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Rationale and Early Genitourinary or Gastrointestinal ToxicitiesKrishan R Jethwa, Christopher D Hellekson, Jaden D Evans, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 31, 2025
Defining NECTIN4 Amplification and Protein Expression in Urothelial Carcinoma and Histologic SubtypesJohn C Cheville, Jacob J Orme, Sounak Gupta, et al.
Journal of Pain and Symptom Management|May 5, 2025
Olanzapine for Managing Side Effects From Antiangiogenic Tyrosine-Kinase InhibitorsRegina M Koch, Miguel Muniz, Candy S Peskey, et al.
Pageof 7